SCHEMBL6695087

SCHEMBL6695087

CCOC(=O)CC(c1c[nH]c2cc(O)ccc12)C1CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3E A5X5Y0 1/20 0.39
HTR3B O95264 1/20 0.39
HTR3A P46098 1/20 0.39
HTR3D Q70Z44 1/20 0.39
HTR3C Q8WXA8 1/20 0.39
PKM P14618 1/20 0.37
GAA P10253 2/20 0.37
KMT2A Q03164 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA3 P34903 1/20 0.36
GABRA2 P47869 1/20 0.36
GABRB2 P47870 1/20 0.36
HTR2C P28335 2/20 0.35
HTR2A P28223 1/20 0.35
HTR2B P41595 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6163579 0.95 BCHE (0.39) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL6697647 0.83 ALDH1A1 (0.52) KMT2AGABRA1GABRG2GABRB3GABRA3
SCHEMBL6696001 0.80 HTR2C (0.39) PKMGAAKMT2AHTR2CHTR2A
SCHEMBL6165052 0.79 ALDH1A1 (0.47) KMT2AGABRA1GABRG2GABRB3GABRA3
SCHEMBL6165678 0.79 GAA (0.49) PKMGAAKMT2ACYP1A2CYP3A4
SCHEMBL6697051 0.78 GAA (0.52) PKMGAAKMT2A
SCHEMBL6694052 0.78 PKM (0.37) PKMGAAKMT2AHTR2CHTR2A
SCHEMBL6699406 0.77 PKM (0.41) PKMGAAKMT2ACYP1A2CYP3A4
SCHEMBL6170334 0.77 IMPDH2 (0.45) PKMGAAKMT2A
SCHEMBL6696915 0.77 GAA (0.43) PKMGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040138284-A1 Indol-3-yl derivatives WIESNER MATTHIAS 2004-07-15 US disclosed
US-6743810-B2 INTEGRIN INHIBITORS; TUMORS, OSTEOPOROSIS, OSTEOLYTIC DISEASES, SUPPRESSING ANGIOGENESIS, ANTITHROMBOTIC MERCK PATENT GMBH (DE) 2004-06-01 US disclosed
US-20030045728-A1 Liberating 3-substituted indole compound from one of its functional derivatives by treatment with a solvolyzing or hydrogenating agent, amidation, saponification, alkylation or acylation, or salt formation MERCK PATENT GMBH (DE) 2003-03-06 US disclosed
EP-1254133-A2 INDOL-3-YL DERIVATIVES MERCK PATENT GmbH (DE) 2002-11-06 EP disclosed
WO-2001058893-A2 INDOL-3-YL DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITORS MERCK PATENT GMBH (DE) 2001-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030045728-A1 Liberating 3-substituted indole compound from one of its functional derivatives by treatment with a solvolyzing or hydrogenating agent, amidation, saponification, alkylation or acylation, or salt formation IGF1R, IDO1, ITGB3 HTR3E 440/4885HTR3B 468/4885HTR3A 550/4885
US-20040138284-A1 Indol-3-yl derivatives ITGB3, ITGB1, IGF1R HTR3E 126/4885HTR3B 229/4885HTR3A 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.